Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

The antifungal effect of lactoferrin and lysozyme on Candida krusei and Candida albicans.

Samaranayake YH, Samaranayake LP, Wu PC, So M.

APMIS. 1997 Nov;105(11):875-83.

PMID:
9393559
2.

The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei.

Nikawa H, Samaranayake LP, Tenovuo J, Pang KM, Hamada T.

Arch Oral Biol. 1993 Dec;38(12):1057-63.

PMID:
8141667
4.
5.

The effect of antifungal agents on the in vitro susceptibility of Candida albicans to apo-lactoferrin.

Nikawa H, Samaranayake LP, Tenovuo J, Hamada T.

Arch Oral Biol. 1994 Oct;39(10):921-3.

PMID:
7741664
6.

Modulation of the anti-Candida activity of apo-lactoferrin by dietary sucrose and tunicamycin in vitro.

Nikawa H, Samaranayake LP, Hamada T.

Arch Oral Biol. 1995 Jun;40(6):581-4.

PMID:
7677606
7.

The in vitro lysozyme susceptibility of Candida albicans cultured in carbohydrate-supplemented media.

Samaranayake YH, MacFarlane TW, Aitchison TC, Samaranayake LP.

Oral Microbiol Immunol. 1993 Jun;8(3):177-81.

PMID:
8233572
8.

The in vitro lysozyme susceptibility of Candida species cultured in sucrose supplemented media.

Samaranayake YH, MacFarlane TW, Samaranayake LP, Aitchison TC.

Microbios. 1993;74(298):23-8.

PMID:
8336552
9.

Fungicidal effect of human lactoferrin against Candida albicans.

Soukka T, Tenovuo J, Lenander-Lumikari M.

FEMS Microbiol Lett. 1992 Jan 15;69(3):223-8.

PMID:
1555756
10.

Activated lactoferrin and fluconazole synergism against Candida albicans and Candida glabrata vaginal isolates.

Naidu AS, Fowler RS, Martinez C, Chen J, Tulpinski J.

J Reprod Med. 2004 Oct;49(10):800-7.

PMID:
15568403
11.

Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces.

Samaranayake YH, Cheung BP, Parahitiyawa N, Seneviratne CJ, Yau JY, Yeung KW, Samaranayake LP.

Arch Oral Biol. 2009 Feb;54(2):115-26. doi: 10.1016/j.archoralbio.2008.09.015. Epub 2008 Nov 26.

PMID:
19038377
12.

In vitro susceptibility of oral Candida to seven antifungal agents.

Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA.

Oral Microbiol Immunol. 2005 Dec;20(6):349-53.

PMID:
16238594
13.
14.

In vitro susceptibility of Candida species to lactoferrin.

Xu YY, Samaranayake YH, Samaranayake LP, Nikawa H.

Med Mycol. 1999 Feb;37(1):35-41.

PMID:
10200932
15.

Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Krcmery V, Barnes AJ.

J Hosp Infect. 2002 Apr;50(4):243-60. Review.

PMID:
12014897
16.

Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey.

Fadda ME, Podda GS, Pisano MB, Deplano M, Cosentino S.

J Prev Med Hyg. 2008 Jun;49(2):69-74.

PMID:
18847180
17.
18.

Salivary lactoferrin in HIV-infected children: correlation with Candida albicans carriage, oral manifestations, HIV infection and its antifungal activity.

Alves TP, Simões AC, Soares RM, Moreno DS, Portela MB, Castro GF.

Arch Oral Biol. 2014 Aug;59(8):775-82. doi: 10.1016/j.archoralbio.2014.04.010. Epub 2014 Apr 21.

PMID:
24837476
19.

The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.

Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, Vazquez JA, Rampalo A; HIV Epidemiology Research Study (HERS) Group.

J Infect Dis. 2001 Jan 15;183(2):286-93.

PMID:
11204125
20.

Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents.

Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H.

Microbiol Immunol. 1996;40(11):821-5.

Supplemental Content

Support Center